| SCHEDULE of SEGMENT INFORMATION |
SCHEDULE
of SEGMENT INFORMATION
| |
|
2022 |
|
|
2021 |
|
| |
|
For the Three Months Ended January
31, |
|
| |
|
2022 |
|
|
2021 |
|
| |
|
(in thousands) |
|
| Net loss: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,611 |
) |
|
$ |
(960 |
) |
| Cancer Vaccines |
|
|
(1,357 |
) |
|
|
(906 |
) |
| Anti-Viral Therapeutics |
|
|
(904 |
) |
|
|
(481 |
) |
| Other |
|
|
(7 |
) |
|
|
115 |
|
| Total |
|
$ |
(3,879 |
) |
|
$ |
(2,232 |
) |
| Net loss |
|
$ |
(3,879 |
) |
|
$ |
(2,232 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,880 |
|
|
$ |
2,746 |
|
| Less
non-cash share-based compensation |
|
|
(2,354 |
) |
|
|
(986 |
) |
Operating
costs and expenses excluding
non-cash share-based compensation |
|
$ |
1,526 |
|
|
$ |
1,760 |
|
Operating costs and expenses excluding non-cash
share based compensation expense: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
669 |
|
|
$ |
558 |
|
| Cancer Vaccines |
|
|
480 |
|
|
|
538 |
|
| Anti-Viral Therapeutics |
|
|
372 |
|
|
|
271 |
|
| Other |
|
|
5 |
|
|
|
393 |
|
| Total |
|
$ |
1,526 |
|
|
$ |
1,760 |
|
Operating costs and expenses excluding non-cash
share based compensation expense |
|
$ |
1,526 |
|
|
$ |
1,760 |
|
| |
|
January
31, 2022 |
|
|
October
31, 2021 |
|
| |
|
(in thousands) |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
15,412 |
|
|
$ |
15,068 |
|
| Cancer Vaccines |
|
|
11,052 |
|
|
|
13,276 |
|
| Anti-Viral Therapeutics |
|
|
8,562 |
|
|
|
7,368 |
|
| Other |
|
|
212 |
|
|
|
545 |
|
| Total |
|
$ |
35,238 |
|
|
$ |
36,257 |
|
| Total Asset |
|
$ |
35,238 |
|
|
$ |
36,257 |
|
|